Evidence map›Paper›PMID 31652564›Full record

ArticleBrain sciences2019

Assessing the Effects of Cytoprotectants on Selective Neuronal Loss, Sensorimotor Deficit and Microglial Activation after Temporary Middle Cerebral Occlusion.

Julius V Emmrich, Sohail Ejaz, David J Williamson, Young T Hong, Sergey Sitnikov, Tim D Fryer, Franklin I Aigbirhio, Heike Wulff, Jean-Claude Baron

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Knockout of the P2YInternational journal of molecular sciences · 2022
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 4 countries.

Julius V EmmrichStroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1QQ, UK. julius.emmrich@charite.de.
Sohail EjazStroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1QQ, UK. drsohailejaz@gmail.com.
David J WilliamsonWolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1QQ, UK. djw84@cam.ac.uk.
Young T HongWolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1QQ, UK. yth20@cam.ac.uk.
Sergey SitnikovStroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1QQ, UK. s.l.sitnikov@gmail.com.
Tim D FryerWolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1QQ, UK. tdf21@wbic.cam.ac.uk.
Franklin I AigbirhioWolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1QQ, UK. fia20@medschl.cam.ac.uk.
Heike WulffDepartment of Pharmacology, School of Medicine, University of California Davis, Davis, CA 95817, USA. hwulff@ucdavis.edu.
Jean-Claude BaronStroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1QQ, UK. Jean-claude.baron@inserm.fr.
University of Cambridge · GBUniversity of California, Davis · US

Funding

Microglial K+ Channels in Ischemic StrokeR01NS100294 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WULFF, HEIKE · 2017 to 2020
$1.3M
Fourth Framework Programme EUSTROKE Health-F2-2008-2022131National Institute of Neurological Disease and Stroke NS100294NINDS NIH HHS R01 NS100294
6 · The paper itself

Abstract

Although early reperfusion after stroke salvages the still-viable ischemic tissue, peri-infarct selective neuronal loss (SNL) can cause sensorimotor deficits (SMD). We designed a longitudinal protocol to assess the effects of cytoprotectants on SMD, microglial activation (MA) and SNL, and specifically tested whether the KCa3.1-blocker TRAM-34 would prevent SNL. Spontaneously hypertensive rats underwent 15 min middle-cerebral artery occlusion and were randomized into control or treatment group, which received TRAM-34 intraperitoneally for 4 weeks starting 12 h after reperfusion. SMD was assessed longitudinally using the sticky-label test. MA was quantified at day 14 using in vivo [

Indexed as

ischemic strokeKCa3.1microglial activationPETreperfusion injuryselective neuronal lossTRAM-34

Identifiers

PMID31652564
PMCPMC6827002
OpenAlexW2981751912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.